Background: Glutathione S-transferases (GSTs) are encoded by a superfamily of genes and play a role in the detoxification of potential carcinogens. In a nested case-control study, we investigated associations between genetic variability in specific GST genes (GSTM1, GSTT1, and GSTP1) and susceptibility to breast cancer. Methods: In 1989, a total of 32 898 individuals donated blood samples to a research specimen bank established in Washington County, MD. Genotypes of blood specimen DNA were determined for 110 of 115 women with incident cases of breast cancer diagnosed during the period from 1990 through 1995 and up to 113 of 115 control subjects. Associations between specific genotypes and the development of breast cancer were examined by use of logistic regression to calculate odds ratios (ORs) and 95% confidence intervals (CIs). Results: The GSTM1 homozygous null genotype was associated with an increased risk of developing breast cancer (OR = 2.10; 95% CI = 1.22-3.64), principally due to an association with postmenopausal breast cancer (OR = 2.50; 95%CI = 1.34-4.65). For GSTP1, the data were suggestive of a trend of increasing risk with higher numbers of codon 105 valine alleles (compared with isoleucine alleles); a 1.97-fold increased risk of
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A large proportion of breast cancer cases cannot be attributed to known risk factors. Further insight into the etiology of breast cancer may be gained by identifying susceptibility factors that predispose individuals to breast cancer if they are exposed to particular environmental agents. An example of such candidate susceptibility factors would include inherited differences in carcinogen metabolism as observed for the N-acetyltransferases and glutathione S-transferases (GSTs). A report (1) supporting this model suggests that low-activity N-acetyltransferase genotypes may predispose women to breast cancer induced by cigarette smoking. The GSTs are a superfamily of genes whose gene products catalyze the conjugation of reactive chemical intermediates to soluble glutathione (2) . Of particular interest, GSTM1 and GSTP1 can detoxify carcinogenic polycyclic aromatic hydrocarbons, such as benzo [a] pyrene and the mycotoxin aflatoxin, while GSTT1 can detoxify smaller reactive hydrocarbons, such as ethylene oxide and diepoxybutane (3) . In addition, glutathione transferases may have a role in the metabolism of lipid and DNA products of oxidative stress (4, 5) and also in the resistance to cancer chemotherapeutic agents (6) .
In humans, hereditary differences in specific GST enzyme activities are due to genetic polymorphisms (7, 8) . GSTM1 enzyme activity is absent in about 45%-50% of Caucasian populations (8) (9) (10) (11) (12) (13) .
The absence of GSTM1 activity is caused by inheritance of two null alleles (alleles that have a deletion of the GSTM1 gene); similarly, individuals with no GSTT1 activity also have inherited null alleles of the GSTT1 gene. The GSTM1 null genotype has been associated with an increased risk of lung, bladder, and colon cancers (5, (8) (9) (10) (11) 14) . The GSTT1 null genotype has been associated with an increased risk of ulcerative colitis (15), colorectal cancer (16) , and myelodysplastic syndromes (17) . A coding sequence polymorphism, A313G (changing codon 105 from Ile to Val), in the GSTP1 gene was identified several years ago (18) , but little information has been published about how it affects GSTP1 phenotype in human tissues or its association with cancer risk. Zimniak et al. (19) reported that the GSTP1 105 Val allele had reduced catalytic activity when expressed in Escherichia coli, and recent experiments from our laboratory (20) suggest that the 105 Val allele was associated with lower GSTP1 enzyme activity in lung tissue samples. The GSTP1 enzyme can mediate the detoxification of numerous chemicals including chemotherapy agents (e.g., alkylating agents). Increased expression of GSTP1 in tumors has been hypothesized to play a role in the drug resistance seen in many cancers, and this phenomenon has been observed in cancers of the breast, head and neck, and skin and in acute leukemia (21) (22) (23) (25) . Future investigations would benefit from stronger study designs.
To investigate the association between genetic variability in GSTM1, GSTT1, and GSTP1 and risk of breast cancer, a nested case-control-subject study was conducted by use of a specimen bank established in Washington County, MD, in 1989.
Subjects and Methods

Study Population
In 1989, a research specimen bank was established with 32 898 individuals donating a blood sample after they signed an informed consent. Of the participants, 25 081 (14 625 women) were residents of Washington County and formed the study cohort. Compared with the Washington County population, the cohort participation rates were higher among women and older individuals. Incident breast cancer cases (n ‫ס‬ 115) occurring during the period from 1990 through 1995 were identified by linkage of the study cohort to the Washington County Cancer Registry. Eleven of the 115 case patients had ductal carcinoma in situ. The registry identifies case patients from discharge records of the Washington County Hospital, the only hospital in the county, and from death certificates. To estimate completeness of ascertainment of the Washington County Cancer Registry, we compared the number of cancer cases obtained through the registry with the number reported to the Maryland Cancer Registry for Washington County for a 1-year period. The Maryland Cancer Registry has mandatory reporting of incident breast cancer cases from hospitals, pathology laboratories, and physicians throughout Maryland (26) . The first complete report of the state registry was for 1993. In that year, 89 cases of breast cancer were recorded in the Washington County Cancer Registry, and 81 incident cases were reported to the Maryland Cancer Registry.
Each case patient was matched to one control subject on age (within 1 year), race (all were white), menopausal status, time from last menstrual period, and date of blood donation within 2 weeks.
At the time of blood donation, participants completed a brief questionnaire that ascertained smoking status, height, weight, and medication taken in the previous 48 hours. As part of a larger study on environmental risk factors and breast cancer, case patients and control subjects were sent a selfadministered questionnaire in 1995 to obtain more detailed information about risk factors for breast cancer. Of the 115 case patients, 104 (90.4%) returned the completed questionnaire; of the 115 control subjects, 103 (89.6%) returned the completed questionnaire. Exposure to such factors as hormone replacement therapy among case patients and control subjects was truncated at the date of diagnosis of the case patient.
Laboratory Assays
Blood was collected in 20-mL heparinized tubes and centrifuged at 1500g for 30 minutes at room temperature within 6 hours of collection. Plasma, buffy coat, and red blood cells were separated and stored at −70°C within 24 hours of collection. The buffy coat was kept frozen until it was thawed for DNA extraction for this study.
DNA was extracted from the thawed white blood cell fraction from each study subject by high-salt fractionation (27) followed by chloroform-isoamyl alcohol extraction (28) . The concentration of DNA was adjusted to 100 g/mL, and the DNA was stored at −70°C until genotype analysis. DNA of sufficient quality for all three genotype analyses was successfully extracted from 110 of 115 case patients and up to 113 of 115 control subjects. GSTM1 and GSTT1 genotypes were determined by use of the multiplex polymerase chain reaction (PCR) method of Chen et al. (17) . This technique does not distinguish between heterozygote and homozygote GSTM1-or GSTT1-positive genotypes, but it conclusively identifies null genotypes. The GSTP1 (Ile105Val) genotype was determined by use of the PCR-restriction fragment length polymorphism method of Watson et al. (20) . Briefly, genomic DNA (50 ng) was added to a PCR mix of GSTP1 primers 2306F (5Ј-GTA GTT TGC CCA AGG TCA AG) and 2721R (5Ј-AGC CAC CTG AGG GGT AAG) (15 pmol each), deoxynucleoside triphosphates (200 mol each), 0.5 U Taq polymerase (Amplitaq; The Perkin-Elmer Corp., Norwalk, CT) in buffer composed of 16.6 mM (NH 4 ) 2 SO 4 , 50 mM ␤-mercaptoethanol, 6.8 M ethylene diaminetetraacetic acid (EDTA), 67 M Tris, 80 g/mL bovine serum albumin, and 2.0 mM MgCl 2 . The mixture was assembled at 85°C and placed in a PerkinElmer 9600 thermocycler at 94°C. After an initial denaturation step at 94°C for 3 minutes, five cycles of PCR were carried out (cycle 1: 94°C for 15 seconds, 64°C for 30 seconds, and 72°C for 60 seconds) during which the annealing temperature decreased by 1°C for each cycle (20) . This step was followed by 25 cycles of amplification at 94°C for 15 seconds, 59°C for 30 seconds, and 72°C for 60 seconds and a final extension at 72°C for 5 minutes.
The high initial annealing temperature (64°C) followed by decreasing temperatures in the PCR program was found to reduce the appearance of nonspecific amplification products (20) . PCR products were digested for 4-16 hours with the restriction enzyme Alw26I, which distinguishes between the restriction sites on the Ile allele (ACA TCT) and the Val allele (ACG TCT.) Products of PCR amplification or restriction digests were analyzed by gel electrophoresis, and genotypes were determined by characteristic band patterns on the gel. The GSTP1-genotyping method has primers that flank an Alw26I restriction site that is present in all samples, thus providing a control cut for the restriction digest portion of the assay (20) .
To ensure laboratory quality control, two independent readers interpreted the gel photographs. Any sample with ambiguous results (generally due to low PCR yield) was retested, and a random selection of 10% of all samples was repeated. No discrepancies were discovered upon replicate testing.
Statistical Analysis
The association between the GSTM1, GSTT1, and GSTP1 genotypes and the development of breast cancer was examined by use of conditional and unconditional logistic regression analyses to calculate the odds ratios (ORs) and 95% confidence intervals (CIs). The GST assays place individuals into distinct categories: those with present or null genotypes for GSTM1 and GSTT1 and those with homozygous Ile/Ile or with heterozygous or homozygous 105 Val allele for GSTP1. ORs and 95% CIs were estimated for each of these categories with the present genotype (GSTM1 and GSTT1) or homozygous Ile/Ile (GSTP1) designated as the referent category.
Of interest was the relationship between the GST genotypes and the development of breast cancer within categories of risk factors to assess for the presence of confounding and interaction. The specific variables used in these stratified analyses were menopausal status of the case patient at the time of diagnosis, smoking history, history of alcohol consumption, body mass index (BMI), ever use of hormone replacement therapy, and family history of breast cancer in mother, sister, or grandmother. For most of these variables, stratified analyses required breaking the match to preserve adequate numbers in the strata. Consequently, ORs presented were estimated by use of unconditional logistic regression, adjusting for the matching factors of age and menopausal status at the time of blood donation. For the analyses in which both could be estimated, unmatched analyses produced results similar to those produced by the matched analyses. Logistic regression analysis adjusting for known or suspected risk factors for breast cancer (age at menarche and first birth, family history, BMI, alcohol consumption, exogenous hormone use, and smoking history) did not alter the point estimates of the ORs; therefore, only unadjusted analyses or analyses adjusting only for matching factors are presented.
Women with breast cancer were classified as postmenopausal at diagnosis on the basis of their response to questionnaire items concerning the date of their last menstrual period as well as history of hysterectomy and oophorectomy. Women with information missing in regard to their last menstrual period or women with a history of hysterectomy without oophorectomy were considered to be postmenopausal if they were diagnosed after the age of 51 years (the median age of menopause).
Tests for interaction were based on the P value (two-sided) of the likelihood ratio test for adding the interaction term (genotype by stratified variable) to the model that already included the main effect variable (genotype), stratified variable, age, and menopausal status at baseline.
Results
The association between presumed risk factors and the development of breast cancer is shown in Table 1 .
Ever use of oral contraceptives was similar for case patients and control subjects. Fewer case patients than control subjects reported ever using hormone replacement therapy, but the difference was not statistically significant. Neither cigarette smoking nor alcohol intake was associated with the development of breast cancer. Twenty-eight case patients were premenopausal at the time of diagnosis.
The risk of breast cancer associated with GST genotypes, stratified by menopausal status at the time of diagnosis of the case patient, is shown in Table 2 (Table 3) . Because the risk associated with the null GSTM1 genotype was observed only among postmenopausal breast cancer case patients, in Table 3 the results for GSTM1 are shown stratified by menopausal status at the time of diagnosis of the case patient. While statistical power to detect gene-environment interaction was limited in this study, significant interactions were observed between GSTM1 and BMI and between GSTT1 and a history of alcohol consumption (Table 3) . Postmenopausal women null for GSTM1 and having a BMI above the median (>24.47 kg/m 2 ) had a sevenfold increase in breast cancer risk, whereas women null for GSTM1 and having a BMI less than the median were not at increased risk of breast cancer. Among women with the null GSTT1 genotype, a significant increase in risk was observed only for women who ever reported alcohol intake. GSTM1, GSTT1, and GSTP1 are involved in detoxification of a variety of compounds, some that overlap between enzymes and some that are highly specific (2) . To investigate whether profiles of GST genotypes may be associated with the risk of breast cancer, we examined the risk of breast cancer associated with combinations of genotypes. The reference group consisted of individuals with all three putative low-risk genotypes, i.e., the presence of GSTM1 and GSTT1 genotypes and the homozygous Ile/Ile genotype for GSTP1. Individuals heterozygous and homozygous for the Ile105Val allele were combined for this analysis. Table 4 displays the risk of breast cancer associated with each combination of genotypes as well as the trend in risk associated with one, two, or three putative high-risk genotypes. The presence of at least one putative high-risk genotype was associated with an increased risk of breast cancer. The risk of breast cancer increased as the number of putative high-risk genotypes increased (P for trend <.001).
Discussion
The glutathione transferases are involved in the metabolism of a wide variety of potential carcinogenic compounds, and the isozymes have distinct but overlapping substrate specificity. These substrates include polycylic aromatic hydrocarbon diol-epoxides, organic epoxides, peroxides, N-acetyl benzoquinoneimine, hydroxyalkyl-arenes, and steroids. Several classes of compounds have been identified as mammary carcinogens in animals [e.g., aromatic amino/nitro compounds and epoxide-forming chemicals (29) ], and aromatic DNA adducts have been found in higher levels in breast tissue from cancer patients than in breast tissue from control subjects without cancer (30, 31) . Thus, it is biologically plausible that low-activity-level genotypes would be associated with an enhanced susceptibility to cancer. In this community-based, prospective study, we observed an increased risk for breast cancer associated with the GSTM1 null genotype, GSTP1 105 Val allele genotypes, and the combined GST at-risk genotypes. For GSTP1, the results were suggestive of a linear increase in risk for the heterozygous and homozygous 105 Val genotypes that reflect intermediate and low levels of enzyme activity. These associations did not vary significantly by age of onset of breast cancer, smoking history, alcohol intake, or history of exogenous hormone use. Women who developed breast cancer were about 1.5 times more likely than control subject women to have the GSTT1 null genotype, but this association was not statistically significant.
The significant association that we observed between the null GSTM1 genotype and breast cancer risk is not consistent among three other published reports (12, 13, 32) . Zhong et al. (32) reported results of a multi-cancer (breast, bladder, and colorectal cancers), hospital-based study with case patient samples collected from multiple hospitals in the U.K. and control samples collected from other locations in Scotland. No information was provided on the age, sex, menopausal status, clinical status, or any other possible risk factors of either case patients or control subjects. Zhong et al. found a GSTM1 null genotype frequency of 41.8% among control subjects and of 47.7% among breast cancer case patients; however, the difference in proportions was not statistically significant. Ambrosone et al. (12) carried out a population-based, casecontrol study of postmenopausal breast cancer and reported no increased risk associated with the GSTM1 null genotype among the total study group of 216 case patients and 282 community-based control subjects (OR ‫ס‬ 1.10; 95% CI ‫ס‬ 0.73-1.64). An increased risk associated with the GSTM1 null genotype was observed only among postmenopausal women under the age of 58 years at diagnosis, but this increase was not statistically significant (OR ‫ס‬ 2.44; 95% CI ‫ס‬ 0.89-6.64). A study of prevalent versus incident cases of breast cancer (13) observed a risk of 1.3 (95% CI ‫ס‬ 0.91-1.86) associated with the null genotype among prevalent cases and a risk of 1.08 (95% CI ‫ס‬ 0.74-1.57) among incident cases. Among prevalent cases, the propor- tion of women with breast cancer who had the null genotype increased with increasing duration of survival (13) . The primary difference in our study population compared with other study populations was the percentage of case patients with the GSTM1 null genotype. One could speculate that the different results among the studies could be due to differences in exposures relevant to breast cancer. The GSTP1 family of glutathione transferases is involved in the metabolism of alkylating agents used in chemotherapy, and prior studies have focused on measuring enzyme activity levels in tumor tissues as a potential factor in drug resistance. Harries et al. (24) recently analyzed GSTP1 Ile105Val alleles in a control series and in a series of patients who had a variety of cancers. No information was provided on the age, sex, menopausal status, or clinical status of the control group. Harries et al. found the likelihood of GSTP1 Ile105Val heterozygosity to be 1.5 times higher among breast cancer patients than among control subjects (95% CI ‫ס‬ 0.79-2.98) and homozygosity for Val/Val to be 1.6 times higher among breast cancer patients than among control subjects (95% CI ‫ס‬ 0.42-5.70). A statistically significant increased risk was observed among patients with testicular and bladder cancers. The study by Harries et al., like the previously mentioned study by Zhong et al. (32) , suffers from design weaknesses, such as lack of characterization of cancer case patients and control subjects and exploration of potential confounding. The present study has the strength of a prospective study design with information about other risk factors for breast cancer.
Our findings suggest that genetic differences in some members of the glutathione transferase gene family, which code for phase II detoxification enzymes, may be associated with an increased susceptibility to breast cancer. A statistically significant increase in the risk of breast cancer was observed with increasing burden of putative high-risk genotypes. Significant elevations in the risk of cancer are likely to be observed only among those individuals with the susceptibility genotype as well as with a history of the relevant environmental exposure. The differences in results among the reported studies may be due to variations in the study populations and their exposures. As stated previously, the glutathione transferases are involved in the detoxification of many electrophilic substances, only some of which may be relevant to breast carcinogenesis. Thus, the search must be continued to identify the relevant environmental or endogenous exposures involved in the potential gene-environment interactions. A possible relevant endogenous exposure is estrogen and its catechol metabolites of estrogen (33) . In support of this hypothesis are two findings. First, we observed statistically significant interaction between the BMI and the GSTM1 genotype and the risk of breast cancer. Obesity is a known risk factor for breast cancer, thought to be due to peripheral conversion of androgens to estrogen (34) . Second, catechol-O-methyltransferase is involved in the inactivation of catechol estrogen metabolites. When we examined the risk of postmenopausal breast cancer according to catechol-O-methyltransferase polymorphism for low activity, we found an increased risk among individuals with either the GSTM1 null genotype or the GSTP1 105-Val homozygous or heterozygous genotype (35) . A possible explanation for observing this interaction is the role of glutathione transferases in the metabolisms of the reactive catechol metabolites. Because the suggested highrisk genotypes occur quite commonly, the calculated population attributable risk may be high, even with relatively moderate magnitudes of associated risk. For example, assuming a 44% frequency of the null GSTM1 genotype in the population and an associated twofold increased risk of breast cancer, the percentage of breast cancer cases attributed to the null GSTM1 genotype would be estimated to be 30.5%. If the relevant exogenous exposure that increases risk could be determined and avoided among individuals with these susceptible genotypes, then a substantial proportion of breast cancer cases potentially can be prevented. Such calculations are instructive because they highlight the potential importance of this line of inquiry, but they should be considered premature. These findings need to be replicated in other populations before we can be certain that GST polymorphisms are truly involved in the etiology of breast cancer.
